CIK 0001088856 · Large accelerated filer
CORCEPT THERAPEUTICS INC
Sign in to watch- Ticker
- CORT
- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- FY end
- Dec 31
- Incorporated
- DE
- Entity type
- operating
- EIN
- 770487658
- Phone
- 650.688.8803
- Business address
- 101 REDWOOD SHORES PARKWAY, REDWOOD CITY, CA, 94065
- Open-market buys, last 90 days
- $0
- in 0 filings
- Open-market sales, last 90 days
- $41,067,988
- in 15 filings, $36.6M under 10b5-1 plans
Net −$41,067,988. Shares bought or sold at a price by officers, directors and 10% owners (Form 4 codes P and S). Grants, option exercises and tax withholding aren't counted.
Who's trading
90 days
Reading 100 more Form 4s from the SEC; this list fills in as they're read.
| Date | Insider | Transaction | Shares | Price | Value | Owned after |
|---|---|---|---|---|---|---|
| 2024-09-03 | Maduck Sean See Remarks | Grant or award | +458 | 85,083 | ||
| 2024-09-03 | Guyer William Chief Development Officer | Option exercise 10b5-1 | +10,000 | $21.65 | $217K | 16,039 |
| 2024-09-03 | Guyer William Chief Development Officer | Sale 10b5-1 | −10,000 | $35.30 | $353K | 6,039 |
| 2024-09-03 | Guyer William Chief Development Officer | Shares withheld for taxes 10b5-1 | −243 | $35.30 | $9K | 5,796 |
| 2024-09-03 | Guyer William Chief Development Officer | Option exercise · Stock option (right to buy) 10b5-1 | −10,000 | 470,000 | ||
| 2024-09-03 | Robb Gary Charles Chief Business Officer | Shares withheld for taxes | −254 | $35.30 | $9K | 22,936 |
| 2024-09-03 | Robb Gary Charles Chief Business Officer | Grant or award | +503 | $34.26 | $17K | 23,439 |
| 2024-09-03 | Robb Gary Charles Chief Business Officer | Grant or award | +503 | 23,942 | ||
| 2024-08-26 | Robb Gary Charles Chief Business Officer | Sale | −3,101 | $35.71 | $111K | 23,190 |
| 2024-08-01 | Swisher Daniel N JR Director | Option exercise 10b5-1 | +150 | $5.86 | $879 | 150 |
| 2024-08-01 | Swisher Daniel N JR Director | Sale 10b5-1 | −150 | $38.50 | $6K | 0 |
| 2024-08-01 | Swisher Daniel N JR Director | Option exercise · Stock option (right to buy) 10b5-1 | −150 | 0 | ||
| 2024-08-01 | Guyer William Chief Development Officer | Option exercise 10b5-1 | +10,000 | $21.65 | $217K | 16,039 |
| 2024-08-01 | Guyer William Chief Development Officer | Sale 10b5-1 | −10,000 | $38.67 | $387K | 6,039 |
| 2024-08-01 | Guyer William Chief Development Officer | Option exercise · Stock option (right to buy) 10b5-1 | −10,000 | 480,000 | ||
| 2024-08-01 | Hunt Hazel Chief Scientific Officer | Option exercise | +60,000 | $2.81 | $169K | 153,354 |
| 2024-08-01 | Hunt Hazel Chief Scientific Officer | Shares withheld for taxes | −34,773 | $37.94 | $1.3M | 118,581 |
| 2024-08-01 | Hunt Hazel Chief Scientific Officer | Option exercise · Stock Option (right to buy) | −60,000 | 0 | ||
| 2024-07-31 | BELANOFF JOSEPH K Chief Executive Officer | Option exercise | +450,000 | $3.29 | $1.5M | 798,811 |
| 2024-07-31 | BELANOFF JOSEPH K Chief Executive Officer | Shares withheld for taxes | −259,583 | $38.67 | $10.0M | 539,228 |
Page 36 of 61 · 1,220 trades